Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OraTech Pharmaceuticals
New York City, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Phase 3 studies for oral insulin using the proprietary POD™ oral delivery platform are set to resume in the United States; registration activities also advancing in China, with a Marketing Authorization Application submitted. In prior Phase 3, ORMD-0801 did not meet endpoints, but new trials are based on identified responder subgroups. Commercialization preparations underway in China with HTIT as manufacturing and supply partner.
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- ProteinOral drug deliveryBiologic
- Industry
- Biotech
02
Partnerships
Oramed PharmaceuticalsHefei Tianhui Biotech (HTIT)
Beyond the preview
Go deeper on OraTech Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OraTech Pharmaceuticals.